Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 Oct 1.

Published in final edited form as: Placenta. 2010 Aug 14;31(10):886–892. doi: 10.1016/j.placenta.2010.07.012

Thrombin effect upon MMP9 and MMP3 in Choriodecidua: Thrombin (0–100 u/ml for 48 h) failed to show concentration-dependent increases in pro-MMP9 (92 kD) in the choriodecidua component of treated FM explants. The active MMP9 (78 kD) form was not detected (Panel A). Thrombin (0–100 u/ml for 48 h) failed to show concentration-dependent increases in either the pro-MMP3 (57 kD) or the active MMP3 (45 kD) protein in the choriodecidual component of treated FM explants (Panel B). The Western blot shown is representative of three replicate experiments with three different placentas. To confirm the significance of qualitative results, triplicate blots were scanned and subjected to densitometric analysis. Each blot was normalized to the zero-thrombin controls as indicated in Methods. (Data are presented mean ± SD, no significant differences were detected.)

Thrombin effect upon MMP9 and MMP3 in Choriodecidua: Thrombin (0–100 u/ml for 48 h) failed to show concentration-dependent increases in pro-MMP9 (92 kD) in the choriodecidua component of treated FM explants. The active MMP9 (78 kD) form was not detected (Panel A). Thrombin (0–100 u/ml for 48 h) failed to show concentration-dependent increases in either the pro-MMP3 (57 kD) or the active MMP3 (45 kD) protein in the choriodecidual component of treated FM explants (Panel B). The Western blot shown is representative of three replicate experiments with three different placentas. To confirm the significance of qualitative results, triplicate blots were scanned and subjected to densitometric analysis. Each blot was normalized to the zero-thrombin controls as indicated in Methods. (Data are presented mean ± SD, no significant differences were detected.)